Circular 15 November 2024: Dasatinib Second Line Therapy in Chronic Myeloid Leukaemia
The South African National Cancer Registry, lists 268 new leukaemia cases in 2022. The registry does not make provision for the reporting of the different types of leukaemia – it also does not differentiate between acute and chronic leukaemia. Approximately 15 to 20% of new adult leukaemia diagnoses are CML and although the incidence of cases refractory/intolerant to imatinib will be low, due to
The South African National Cancer Registry, lists 268 new leukaemia cases in 2022. The registry does not make provision for the reporting of the different types of leukaemia – it also does not differentiate between acute and chronic leukaemia. Approximately 15 to 20% of new adult leukaemia diagnoses are CML and although the incidence of cases refractory/intolerant to imatinib will be low, due to long term survival of patients on therapy prevalence will be higher and may increase over time. Current utilization of nilotinib/dasatinib suggest approximately 280 patients nationwide on second line therapy.
Click here to access the circular.